Medtronic and Genzyme Combine Their Cell Therapy Approaches to Serious Heart Disease

To help guide it through the world of cardiac biologics, Medtronic's enlisted the help of biotech Genzyme. Medtronic has drug delivery devices and imaging expertise: Genzyme offers focused cell therapy research in cardiac repair and heart disease and has an up-and-running Phase II trial using autologous skeletal myoblasts. Both companies label the deal as strategic--for now. But 2006 is presumably the earliest newly formed MG Biotherapeutics will begin to commit heavily to this problematic endeavor.

Medtronic Inc. is as well positioned as any device company to explore the first wave of opportunities for developing device/biologic combination products—and potentially revolutionize clinical therapy and the device industry. It has significant plays in two key areas, orthopedic biomaterials and drug eluding stents (DES), with Infuse (the bone-growth factor BMP-2, used in spine repair) and leading cardiac device businesses that should soon include a line of DES.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal

 
• By 

Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.

Rising Leaders 2025: Amir Hefni Puts Optimism Into Action At Resolution Therapeutics

 
• By 

In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.

In Vivo’s 2025 Rising Leaders

 
• By 

The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.